Novel vitamin D analogues are useful for making pharmaceutical compositions for the prevention or treatment of bone disorders such as osteoporosis.
1. A method for treating osteoporosis in humans comprising administering to a human an effective amount of a compound represented by the structural formula:
or a diastereomer thereof.
2. A method for treating osteoporosis in humans comprising administering to a human an effective amount of a compound having the formula:
or a diastereomer thereof.
3. A method for treating osteoporosis in a human without inducing hypercalcemia, comprising administering to said human an effective amount of a compound having the structural formula:
or a diastereoisomer thereof.
4. A method for the treatment of osteoporosis in a mammal comprising administering to said mammal an effective amount of a vitamin D 3 analogue selected from the group consisting of:
(1R,3R)-5-{(E)-3-((1S,3R)-3-((1S,4R)-4-hydroxy-1,5-dimethylhexyl)-2,2,3-trimethylcyclopentyl)-2-propenylidene)cyclohexane-1,3-diol,
(1R,3S)-5-((Z,2E)-3-((1S,3R)-3-((1S,4S)-4-hydroxy-1,5-dimethylhexyl)-2,2,3-trimethylcyclopentyl)-2-propenylidene)-4-methylene-cyclohexane-1,3-diol,
(1R,3S)-5-((Z,2E)-3-((1S,3R)-3-((1S,4R)-4-hydroxy-1,5-dimethylhexyl)-2,2,3-trimethylcyclopentyl)-2-propenylidene)-4-methylene-cyclohexane-1,3-diol,
(1R,3S)-5-((Z-2E)-3-((1S,3R)-3-((1S)-6,6,6-trifluoro-5-hydroxy-1-methyl-5-trifluoromethyl-3-hexynyl)-2,2,3-trimethylcyclopentyl)-2-propenylidene)-4-methylenecyclohexane-1,3-diol,
(1R,3S)-5-((Z,2E)-3-((1S,3R)-3-((1R)-6,6,6-trifluoro-5-hydroxy-1-methyl-5-trifluoromethyl-3-hexynyl)-2,2,3-trimethylcyclopentyl)-2-propenylidene)-4-methylenecyclohexane-1,3-diol, and
(1R,3S)-5-((Z,2E)-3-((1S,3R)-3-((1R)-5-hydroxy-1,5-dimethyl-3-hexynyl)-2,2,3-trimethylcyclopentyl)-2-propenylidene)-4-methylenecyclohexane-1,3-diol.
5. The method of claim 4 , wherein said treatment is achieved without the side effect of inducing hypercalcemia in said mammal.
6. A method for treatment of osteoporosis in a human without inducing hypercalcemia, comprising administering to said human a therapeutically effective amount of a vitamin D 3 analogue selected from the group consisting of:
(1R,3R)-5-{(E)-3-((1S,3R)-3-((1S,4R)-4-hydroxy-1,5-dimethylhexyl)-2,2,3-trimethylcyclopentyl)-2-propenylidene)cyclohexane-1,3-diol,
(1R,3S)-5-((Z,2E)-3-((1S,3R)-3-((1S,4S)-4-hydroxy-1,5-dimethylhexyl)-2,2,3-trimethylcyclopentyl)-2-propenylidene)-4-methylene-cyclohexane-1,3-diol,
(1R,3S)-5-((Z,2E)-3-((1S,3R)-3-((1S,4R)-4-hydroxy-1,5-dimethylhexyl)-2,2,3-trimethylcyclopentyl)-2-propenylidene)-4-methylene-cyclohexane-1,3-diol,
(1R,3S)-5-((Z-2E)-3-((1S,3R)-3-((1S)-6,6,6-trifluoro-5-hydroxy-1-methyl-5-trifluoromethyl-3-hexynyl)-2,2,3-trimethylcyclopentyl)-2-propenylidene)-4-methylenecyclohexane-1,3-diol,
(1R,3S)-5-((Z,2E)-3-((1S,3R)-3-((1R)-6,6,6-trifluoro-5-hydroxy-1-methyl-5-trifluoromethyl-3-hexynyl)-2,2,3-trimethylcyclopentyl)-2-propenylidene)-4-methylenecyclohexane-1,3-diol, and
(1R,3S)-5-((Z,2E)-3-((1S,3R)-3-((1R)-5-hydroxy-1,5-dimethyl-3-hexynyl)-2,2,3-trimethylcyclopentyl)-2-propenylidene)-4-methylenecyclohexane-1,3-diol.
7. A method according to claim 6 , wherein said human is selected from the group consisting of postmenopausal women, postoophorectomy women, men with androgen deficiency, and elderly people at risk of osteoporotic fractures.
8. A method according to claim 6 , wherein said therapeutically effective amount is within a range from about 2 to 20 μg per day and per kg body weight of said human.
9. A method for the treatment of osteoporosis in a mammal comprising administering an effective amount of (1R,3R)-5-((E)-3-((1S,3R)-3-((1R)-6,6,6-trifluoro-5-hydroxy-1-methyl-5-trifluoromethyl-3-hexynyl)-2,2,3-trimethylcyclopentyl)-2-propenylidene)cyclohexane-1,3-diol, wherein said treatment is achieved without the side effect of inducing hypercalcemia in said mammal.
10. A method for the treatment of osteoporosis in a human, comprising administering a therapeutically effective amount of (1R,3R)-5-((E)-3-((1S,3R)-3-((1R)-6,6,6-trifluoro-5-hydroxy-1-methyl-5-trifluoromethyl-3-hexynyl)-2,2,3-trimethylcyclopentyl)-2-propenylidene)cyclo-hexane-1,3-diol, wherein said treatment is achieved without the side effect of inducing hypercalcemia in said human.
11. A method according to claim 10 , wherein said human is selected from the group consisting of postmenopausal women, postoophorectomy women, men with androgen deficiency, and elderly people at risk of osteoporotic fractures.
12. A method according to claim 10 , wherein said therapeutically effective amount is within a range from about 2 to 20 μg per day per kg body weight of said human.